Syros Pharmaceuticals (SYRS) 10-Q2019 Q3 Quarterly report

Filed: 12 Nov 19, 7:41am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: academic, acquisition, addressed, advantage, aim, announced, announcement, appetite, area, assign, attention, belief, black, blocking, burdensome, carefully, CDK, characterizing, civil, commonly, compensatory, competitor, compromise, Conference, constipation, contraindication, coronary, coupled, coverage, CR, CRi, criminal, cyclin, decide, departure, discontinuation, discontinue, economic, edema, elucidate, elucidating, eluded, ENA, ESH, experienced, extreme, family, fatigue, feasible, Forty, forward, frequency, GlaxoSmithKline, Guide, Haematology, healthcare, histology, imposition, incidence, increasingly, induced, influenced, infusion, inhibition, internationally, intravenously, IV, Jannsen, landscape, led, lengthening, liable, litigation, lose, lung, Memorial, myelosuppression, nausea, necessitate, negotiate, opt, optimal, outlining, overly, pathway, peak, peripheral, potency, potent, potently, power, prompted, pursuit, raw, Rb, recall, redefine, redesign, renew, renewed, reputation, resource, Richard, satisfactory, School, seize, slightly, snapshot, structure, submission, subset, substance, sued, technical, timeframe, unfit, unidentified, unique, unrelated, unwilling, vasospasm, viable, vomiting, withdraw, Young, Yungjin

Removed: accessible, American, analyze, built, DNA, durable, efficiently, fifteen, fundamental, Hematology, HR, linked, LLC, maximum, mechanism, medicine, Meeting, opened, pioneering, region, Society, Symposium, systematically, unexploited, updated, wave

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated SYRS transcripts

SYRS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Syros Pharmaceuticals, Inc. (the “Company”) for the quarter ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Nancy Simonian, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 12, 2019

/s/ Nancy Simonian, M.D.

Nancy Simonian, M.D.

President and Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.